Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Kura Oncology (KURA)

Kura Oncology (KURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib GlobeNewswire - Fri Apr 17, 5:00AM CDT

Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated...

KURA : 9.78 (+1.03%)
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026 GlobeNewswire - Thu Apr 9, 6:30AM CDT

Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30...

KURA : 9.78 (+1.03%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Apr 3, 6:30AM CDT

SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 9.78 (+1.03%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Mar 6, 6:30AM CST

SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 9.78 (+1.03%)
Kura Oncology: Q4 Earnings Snapshot AP - Thu Mar 5, 5:47AM CST

Kura Oncology: Q4 Earnings Snapshot

KURA : 9.78 (+1.03%)
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Thu Mar 5, 5:31AM CST

– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of...

KURA : 9.78 (+1.03%)
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Thu Feb 26, 6:30AM CST

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...

KURA : 9.78 (+1.03%)
Kura Oncology to Participate in Three Upcoming Investor Conferences GlobeNewswire - Wed Feb 25, 6:30AM CST

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...

KURA : 9.78 (+1.03%)
Doctor holding money by IherPhoto via iStock
1 Under-$10 Stock Set to Surge as Much as 850% in 2026 Barchart - Thu Feb 12, 3:04PM CST

Kura is a classic high-risk, high-reward biotech investment that has entered a vital growth phase.

KURA : 9.78 (+1.03%)
MRNA : 54.59 (+1.62%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Feb 6, 6:30AM CST

SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 9.78 (+1.03%)

Barchart Exclusives

As Costco Raises Its Dividend More Than 13%, Should You Buy, Sell, or Hold COST Stock? Barchart - Mon Apr 20, 6:30PM CDT
Costco raised its quarterly dividend 13.1% to $1.47 per share. Here's what investors need to know before deciding to buy, sell, or hold COST stock right now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.